X‑Chem Enters Strategic Collaboration with Bristol-Myers Squibb
WALTHAM, Mass. – December 18, 2018 – X-Chem, Inc., a privately held biotechnology company focused on applying its industry-leading DNA-encoded (DEX™) library drug discovery engine to the generation of novel…
Almirall and X‑Chem Announce Dermatology-Focused Drug Discovery Collaboration
WALTHAM, Mass. – December 12, 2018 - X-Chem, Inc. (X-Chem), a privately held biotechnology company applying its innovative drug discovery platform to the generation of novel small molecule therapeutics, announced…
X‑Chem Announces Licensing of 50th Drug Discovery Program
WALTHAM, Mass. – July 26, 2018 – X-Chem, Inc., a privately held biotechnology company focused on applying its industry-leading DNA-encoded (DEXTM) library drug discovery engine to the generation of novel…
X‑Chem spin-off X-Biotix Therapeutics Completes $7 million Series A Financing
WALTHAM, Mass. April 24, 2018 – Small molecule drug discovery specialist X-Chem, Inc. (XChem) today announced that its spin-out company X-Biotix Therapeutics, Inc. (X-Biotix) has secured $7 million in a…
X‑Chem Appoints Christelle Huguet, Ph.D. as Chief Scientific Officer
X-Chem, Inc. today announced the appointment of Christelle Huguet, Ph.D. as Chief Scientific Officer, along with an executive leadership appointment for Matthew Clark, Ph.D. as Senior Vice President, Chemistry.
X‑Chem Announces Licensing of Two Discovery Programs to AbbVie
Small molecule drug discovery specialist XChem, Inc. today announced that AbbVie has exercised options to license two discovery programs. Under the terms of the parties’ 2016 multi-target research collaboration, AbbVie…
X‑Chem Enters Expanded Global Drug Discovery and Technology Transfer Collaboration with AstraZeneca
WALTHAM, Mass. – January 17, 2018 – Small molecule discovery specialist X-Chem, Inc. today announced a significant expansion of their existing global drug discovery collaboration with the global biopharmaceutical company…